Opportunity Information: Apply for PAR 18 181
This NIH grant opportunity (PAR-18-181) supports research aimed at untangling how delirium and Alzheimer's disease and related dementias (ADRD) influence one another. The core problem the FOA targets is the two-way relationship seen in clinical care: people who already have ADRD tend to be more vulnerable to delirium and often do worse when delirium occurs, while people who develop delirium (often during hospitalization, surgery, critical illness, or acute infection) appear more likely to develop later mild cognitive impairment or ADRD and may decline faster than similar patients who never became delirious. The opportunity is meant to move beyond simple association by generating evidence about mechanisms and pathways that explain why these patterns occur and how they can be identified earlier and managed better.
The FOA encourages projects that clarify whether delirium and ADRD share biological pathways, whether one condition accelerates or unmasks the other, or whether both arise from overlapping vulnerabilities such as aging-related brain changes, neurodegeneration, inflammation, vascular injury, synaptic dysfunction, or impaired brain resilience. A major emphasis is on mechanistic insight: studies can look for common, sequential, causative, contributory, or synergistic mechanisms linking delirium and ADRD, including research that examines how acute physiologic stressors interact with an already vulnerable or degenerating brain. The announcement explicitly welcomes work that uses appropriate animal models to study how delirium-like states emerge in the context of aging and neurodegeneration, since experimental models can help isolate triggers and biological cascades that are hard to disentangle in human studies.
Beyond mechanisms, the FOA highlights several practical research directions. One is identifying risk factors that predict delirium onset or worsening among people with ADRD and, conversely, identifying features of delirium that predict later cognitive impairment or dementia. Another is improving diagnosis and assessment when the two conditions overlap, since delirium can be difficult to recognize in someone with pre-existing cognitive impairment, and dementia can be missed or mischaracterized during or after an acute delirium episode. The FOA also supports efforts to define meaningful phenotypes among patients who experience both conditions, for example, subtypes based on symptom profiles, biomarker patterns, precipitants, course and recovery, or differential response to interventions. Finally, the opportunity allows for testing pharmacologic and non-pharmacologic strategies that prevent delirium, treat it, or reduce its downstream impact in patients with ADRD, and likewise strategies that might reduce dementia risk or progression in patients who have experienced delirium. Clinical trials are optional, meaning applicants may propose observational, mechanistic, translational, or interventional work depending on the scientific question.
The funding mechanism is the R21/R33, which is typically used for phased innovation: an early exploratory stage (R21) that can transition to a larger, more definitive stage (R33) if milestones are met. In practice, this structure fits projects where preliminary mechanistic signals, feasibility, or initial phenotyping must be demonstrated before scaling to more extensive validation, longitudinal follow-up, or broader intervention testing. The overall intent is to produce results that improve risk assessment, detection, phenotyping, prevention, and clinical management for both delirium and ADRD, with the long-term goal of reducing poor outcomes such as prolonged cognitive decline, loss of independence, and increased morbidity and mortality.
Administrative details in the source indicate this is a discretionary NIH grant opportunity in the health category (CFDA 93.866). Eligibility is broad and includes many types of U.S. institutions and organizations: state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and certain tribal organizations; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other entities. The FOA also notes additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. (foreign) entities and regional organizations. The original closing date listed in the provided data is January 7, 2020, and no award ceiling or expected number of awards is specified in the excerpt.Apply for PAR 18 181
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (R21/R33 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2017-11-01.
- Applicants must submit their applications by 2020-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-18-181 - Delirium and Alzheimer's Disease and Related Dementias (ADRD)
What is NIH PAR-18-181 focused on?
This NIH funding opportunity supports research that disentangles how delirium and Alzheimer's disease and related dementias (ADRD) influence each other. It targets the two-way relationship seen in clinical care: people with ADRD are often more vulnerable to delirium and tend to have worse outcomes when delirium occurs, and people who experience delirium appear more likely to develop later mild cognitive impairment or ADRD and may decline faster than similar patients who never became delirious.
What problem is the FOA trying to solve beyond identifying associations?
The FOA is intended to move beyond simple statistical associations by generating evidence about mechanisms and pathways that explain why delirium and ADRD are linked. The aim is to support research that helps identify these patterns earlier and manage them more effectively.
What kinds of scientific questions are encouraged?
The FOA encourages projects that clarify whether delirium and ADRD share biological pathways, whether one condition accelerates or unmasks the other, or whether both arise from overlapping vulnerabilities (such as aging-related brain changes, neurodegeneration, inflammation, vascular injury, synaptic dysfunction, or impaired brain resilience).
Is the emphasis more on clinical outcomes or biological mechanisms?
A major emphasis is on mechanistic insight. The FOA highlights studies that investigate common, sequential, causative, contributory, or synergistic mechanisms linking delirium and ADRD, including how acute physiologic stressors interact with a vulnerable or degenerating brain.
Are animal models allowed or encouraged?
Yes. The announcement explicitly welcomes work using appropriate animal models to study delirium-like states in the context of aging and neurodegeneration, since experimental models can help isolate triggers and biological cascades that may be difficult to separate in human studies.
What types of risk factor research does the FOA highlight?
The FOA highlights (1) identifying risk factors that predict delirium onset or worsening among people with ADRD and (2) identifying features of delirium that predict later cognitive impairment or dementia.
Does the FOA address challenges in diagnosing delirium in people who already have dementia?
Yes. It supports improving diagnosis and assessment when delirium and ADRD overlap, recognizing that delirium can be difficult to detect in someone with pre-existing cognitive impairment.
Does the FOA also address the reverse problem (missing dementia during or after delirium)?
Yes. The FOA notes that dementia can be missed or mischaracterized during or after an acute delirium episode, and it supports work aimed at improving assessment under these conditions.
What does the FOA mean by defining "phenotypes"?
It supports efforts to define meaningful phenotypes among patients who experience both delirium and ADRD. Examples include subtypes based on symptom profiles, biomarker patterns, precipitants, course and recovery, or differential response to interventions.
Are intervention studies supported?
Yes. The opportunity allows testing pharmacologic and non-pharmacologic strategies that prevent delirium, treat delirium, or reduce downstream impact in patients with ADRD. It also allows strategies aimed at reducing dementia risk or progression in patients who have experienced delirium.
Are clinical trials required?
No. Clinical trials are optional. Applicants may propose observational, mechanistic, translational, or interventional work depending on the scientific question.
What is the funding mechanism used for this opportunity?
The mechanism is the NIH R21/R33, commonly used for phased innovation. It includes an early exploratory stage (R21) that can transition to a larger, more definitive stage (R33) if milestones are met.
What kinds of projects fit the R21/R33 phased structure described here?
The structure fits projects where preliminary mechanistic signals, feasibility, or initial phenotyping must be demonstrated first (R21) before scaling to more extensive validation, longitudinal follow-up, or broader intervention testing (R33), assuming milestones are achieved.
What are the intended outcomes or impacts of the funded research?
The overall intent is to produce results that improve risk assessment, detection, phenotyping, prevention, and clinical management for both delirium and ADRD, with a long-term goal of reducing poor outcomes such as prolonged cognitive decline, loss of independence, and increased morbidity and mortality.
What agency is offering this grant opportunity?
The opportunity is offered through NIH as a discretionary grant opportunity in the health category.
What is the CFDA number listed for this opportunity?
The excerpt lists CFDA 93.866.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. institutions and organizations, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and certain tribal organizations; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other entities.
Are specific institution types explicitly mentioned as eligible?
Yes. The FOA notes additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, and U.S. territories or possessions.
Can non-U.S. entities apply?
Yes. The FOA states that non-U.S. (foreign) entities and regional organizations are eligible.
What is the application closing date shown in the provided information?
The original closing date listed in the provided data is January 7, 2020.
Is there an award ceiling or a stated expected number of awards?
No. The excerpt does not specify an award ceiling or the expected number of awards.
What settings or triggers for delirium are mentioned as relevant in this FOA?
The description notes delirium often develops during hospitalization, surgery, critical illness, or acute infection, and these acute physiologic stressors are part of what the FOA wants to understand in relation to a vulnerable or degenerating brain.
Browse more opportunities from the same category: Health
Next opportunity: Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
Previous opportunity: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 181
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 181) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (R01 Clinical Trial Optional) Apply for PA 18 191 Funding Number: PA 18 191 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Revision Applications for Validation of Mobile/Wireless Health Tools for Measurement and Intervention (R01) (Clinical Trials Not Allowed) Apply for PA 18 338 Funding Number: PA 18 338 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Phased Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R61/R33 Clinical Trial Required) Apply for PAR 18 114 Funding Number: PAR 18 114 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Outcomes for Disorders of Human Communication (R01 Clinical Trial Optional) Apply for PA 18 287 Funding Number: PA 18 287 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Minority HIV/AIDS Research Initiative (MARI) to Build HIV Prevention, Treatment and Research Capacity in Disproportionately Affected Black and Hispanic Communities and Among Historically Underrepresented Researchers Apply for RFA PS 16 00103CONT18 Funding Number: RFA PS 16 00103CONT18 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: Case Dependent |
| Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33 Clinical Trial Required) Apply for PAR 18 115 Funding Number: PAR 18 115 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Emerging Infectious Sentinel Networks (EISN) Research Apply for RFA CK 16 00103CONT18 Funding Number: RFA CK 16 00103CONT18 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: Case Dependent |
| NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 18 118 Funding Number: PAR 18 118 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Outcomes for Disorders of Human Communication (R21 Clinical Trial Optional) Apply for PA 18 288 Funding Number: PA 18 288 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Population-based HIV Impact Assessments in Resource-Constrained Settings under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1409A Funding Number: CDC RFA GH14 1409A Agency: Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R03 Clinical Trial Required) Apply for PA 18 198 Funding Number: PA 18 198 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R21 Clinical Trial Required) Apply for PA 18 197 Funding Number: PA 18 197 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Systems Biology Approaches using Non-Mammalian Laboratory Animals to Uncover Causes of Neurodegeneration that Might Underlie Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) Apply for RFA AG 18 021 Funding Number: RFA AG 18 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R03 Clinical Trial Optional) Apply for PA 18 200 Funding Number: PA 18 200 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Alcohol Use Disorders: Behavioral Treatment, Services and Recovery Research (R03 Clinical Trial Optional) Apply for PA 18 201 Funding Number: PA 18 201 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Alcohol Use Disorders: Behavioral Treatment, Services and Recovery Research (R21 Clinical Trial Optional) Apply for PA 18 202 Funding Number: PA 18 202 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R01 Clinical Trial Required) Apply for PA 18 192 Funding Number: PA 18 192 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R01 Clinical Trial Optional) Apply for PA 18 193 Funding Number: PA 18 193 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Use Disorders: Behavioral Treatment, Services and Recovery Research (R01 Clinical Trial Optional) Apply for PA 18 194 Funding Number: PA 18 194 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R21 Clinical Trial Optional) Apply for PA 18 199 Funding Number: PA 18 199 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 181", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.